PRAME
| Melanoma antigen preferentially expressed in tumors | ||
|---|---|---|
| other names |
Grandpa-interacting protein 4, OIP-4, PRAME |
|
| Properties of human protein | ||
| Mass / length primary structure | 509 amino acids , 57,890 Da | |
| Identifier | ||
| External IDs | ||
| Orthologue (human) | ||
| Entrez | 23532 | |
| Ensemble | ENSG00000185686 | |
| UniProt | P78395 | |
| Refseq (mRNA) | NM_001291715.1 | |
| Refseq (protein) | NP_001278644.1 | |
| PubMed search |
23532
|
|
PRAME ( English Preferentially Expressed Antigen in Melanoma , “preferably expressed antigen in melanoma”), also Grandpa-interacting protein 4 , CT130 and MAPE , is a protein and tumor antigen from the group of cancer / testis antigens .
properties
PRAME is 509 amino acids long and has a mass of 57,890 Da . It is N -terminal to the serines of the positions 9 and 16 phosphorylated . PRAME also has four leucine-rich repeats (positions 323 - 343, 350 - 371, 379 - 400, 407 - 427). At the C terminus is a RARA binding sequence motif. It inhibits RARA and binds to the retinoic acid receptor . PRAME inhibits apoptosis and cell differentiation . It is believed to be involved in the malignant transformation . However, it induces gene expression of E-cadherin and inhibits metastasis of adenocarcinoma of the lung. It also promotes apoptosis and inhibits cell division in leukemia. PRAME comes as a tumor antigen hardly in normal cells before (except in immune privileged spermatocytes ), but often in different tumors expressing such. B. melanoma , ovarian cancer and seminoma . Furthermore, in contrast to most cancer / testis antigens, it also occurs in leukemia (as a non-solid tumor). PRAME is a target antigen in the development of cancer vaccines and cancer immunotherapies using adoptive cell transfer .
Individual evidence
- ↑ a b c d e N. Hermes, S. Kewitz, MS Staege: Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins. In: Current cancer drug targets. Volume 16, Number 5, 2016, pp. 400-414, PMID 26694250 .
- ^ D. Nettersheim, I. Arndt, R. Sharma, S. Riesenberg, S. Jostes, S. Schneider, M. Hölzel, G. Kristiansen, H. Schorle: The cancer / testis-antigen PRAME supports the pluripotency network and represses somatic and germ cell differentiation programs in seminomas. In: British Journal of Cancer . Volume 115, Number 4, August 2016, pp. 454-464, doi : 10.1038 / bjc.2016.187 , PMID 27441500 .
- ↑ Q. Huang, H. Wei, Z. Wu, L. Li, L. Yao, Z. Sun, L. Li, Z. Lin, W. Xu, S. Han, W. Cao, Y. Xu, D. Song, X. Yang, J. Xiao: Preferentially Expressed Antigen of Melanoma Prevents Lung Cancer Metastasis. In: PloS one. Volume 11, number 7, 2016, p. E0149640, doi : 10.1371 / journal.pone.0149640 , PMID 27391090 , PMC 4938541 (free full text).
- ↑ Y. Xu, Q. Yue, H. Wei, G. Pan: PRAME induces apoptosis and inhibits proliferation of leukemic cells in vitro and in vivo. In: International journal of clinical and experimental pathology. Volume 8, number 11, 2015, pp. 14549-14555, PMID 26823776 , PMC 4713562 (free full text).